PDF(Pubmed)
Abstract：
It has been well assessed that women have been widely under-represented in cardiovascular clinical trials. Moreover, a significant discrepancy in pharmacological and interventional strategies has been reported. Therefore, poor outcomes and more significant mortality have been shown in many diseases. Pharmacokinetic and pharmacodynamic differences in drug metabolism have also been described so that effectiveness could be different according to sex. However, awareness about the gender gap remains too scarce. Consequently, gender-specific guidelines are lacking, and the need for a sex-specific approach has become more evident in the last few years. This paper aims to evaluate different therapeutic approaches to managing the most common women\'s diseases.
摘要：
据充分评估，女性在心血管临床试验中的代表性普遍不足。此外，据报道,药理学和干预策略存在显著差异.因此,在许多疾病中都显示了较差的结局和更显著的死亡率.还描述了药物代谢中的药代动力学和药效学差异，因此有效性可能因性别而异。然而,对性别差距的认识仍然很少。因此,缺乏针对性别的指导方针，在过去的几年中，对特定性别方法的需求变得更加明显。本文旨在评估管理最常见女性疾病的不同治疗方法。
